Controlled trial of D-penicillamine in rheumatoid arthritis. Dose effect and the role of zinc. 1976

C Mery, and F Delrieu, and R Ghozlan, and L Saporta, and F Simon, and B Amor, and C J Menkes, and F Delbarre

The findings are reported of a controlled clinical trial comparing in 66 rheumatoid arthritis patients 0 g (placebo), and 0.50 g a day and 1 g a day of penicillamine. Each of these groups has been subdivided into two, one part receiving 5 mg a day of zinc metal supplement, the other a placebo. The trial was planned to be double-blind, and for each patient to take part for 4 months. The results prove the effectiveness of penicillamine in rheumatoid arthritis. 0.50 g a day has the same effect as 1 g a day but gives less side effects. Zinc supplement inhibits the clinical effects of penicillamine but does not prevent the side effects.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010396 Penicillamine 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. Dimethylcysteine,Mercaptovaline,beta,beta-Dimethylcysteine,Copper Penicillaminate,Cuprenil,Cuprimine,D-3-Mercaptovaline,D-Penicillamine,Metalcaptase,D 3 Mercaptovaline,D Penicillamine,Penicillaminate, Copper,beta,beta Dimethylcysteine
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

C Mery, and F Delrieu, and R Ghozlan, and L Saporta, and F Simon, and B Amor, and C J Menkes, and F Delbarre
February 1973, Lancet (London, England),
C Mery, and F Delrieu, and R Ghozlan, and L Saporta, and F Simon, and B Amor, and C J Menkes, and F Delbarre
May 1983, Arthritis and rheumatism,
C Mery, and F Delrieu, and R Ghozlan, and L Saporta, and F Simon, and B Amor, and C J Menkes, and F Delbarre
August 1982, Arthritis and rheumatism,
C Mery, and F Delrieu, and R Ghozlan, and L Saporta, and F Simon, and B Amor, and C J Menkes, and F Delbarre
July 1973, Annals of the rheumatic diseases,
C Mery, and F Delrieu, and R Ghozlan, and L Saporta, and F Simon, and B Amor, and C J Menkes, and F Delbarre
August 1979, The Ohio State medical journal,
C Mery, and F Delrieu, and R Ghozlan, and L Saporta, and F Simon, and B Amor, and C J Menkes, and F Delbarre
February 1978, Annals of the rheumatic diseases,
C Mery, and F Delrieu, and R Ghozlan, and L Saporta, and F Simon, and B Amor, and C J Menkes, and F Delbarre
September 1976, Lancet (London, England),
C Mery, and F Delrieu, and R Ghozlan, and L Saporta, and F Simon, and B Amor, and C J Menkes, and F Delbarre
January 1986, Indian journal of pediatrics,
C Mery, and F Delrieu, and R Ghozlan, and L Saporta, and F Simon, and B Amor, and C J Menkes, and F Delbarre
January 1979, Harefuah,
C Mery, and F Delrieu, and R Ghozlan, and L Saporta, and F Simon, and B Amor, and C J Menkes, and F Delbarre
March 1984, Arthritis and rheumatism,
Copied contents to your clipboard!